Thyroid hormone alleviates demyelination induced by cuprizone through its role in remyelination during the remission period

Experimental Biology and Medicine

Volumn 240, Issue 9, 2015, Pages 1183-1196

  Zhang, Mao ^a   Zhan, Xiao L ^a   Ma, Zi Y ^a   Chen, Xing S ^a   Cai, Qi Y ^a   Yao, Zhong X ^a  

^a THIRD MILITARY MEDICAL UNIVERSITY   (China)

Author keywords

Corpus callosum; Multiple sclerosis; Myelin; Oligodendrocyte; Thyroid hormone

Indexed keywords

CUPRIZONE; LIOTHYRONINE; MYELIN BASIC PROTEIN; PROPYLTHIOURACIL; THYROID HORMONE;

ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; ASTROCYTE; BLOOD ANALYSIS; BODY WEIGHT; CELL DIFFERENTIATION; CELL PROLIFERATION; CONTROLLED STUDY; CORPUS CALLOSUM; DEMYELINATION; ELECTRON MICROSCOPY; IMMUNOFLUORESCENCE; IMMUNOHISTOCHEMISTRY; MALE; MICROGLIA; MOUSE; NEUROFILAMENT; NONHUMAN; OLIGODENDROGLIA; OPEN FIELD TEST; REMISSION; REMYELINIZATION; ROTAROD TEST; WESTERN BLOTTING; ANIMAL; AXON; C57BL MOUSE; CELL LINEAGE; CHEMICALLY INDUCED; DEMYELINATING DISEASES; DISEASE MODEL; DRUG EFFECTS; HUMAN; MULTIPLE SCLEROSIS, RELAPSING-REMITTING; MYELIN SHEATH; PATHOLOGY; PATHOPHYSIOLOGY; PHYSIOLOGY;

ANIMALS; ASTROCYTES; AXONS; CELL DIFFERENTIATION; CELL LINEAGE; CELL PROLIFERATION; CUPRIZONE; DEMYELINATING DISEASES; DISEASE MODELS, ANIMAL; HUMANS; MALE; MICE; MICE, INBRED C57BL; MICROGLIA; MULTIPLE SCLEROSIS, RELAPSING-REMITTING; MYELIN SHEATH; OLIGODENDROGLIA; THYROID HORMONES;

EID: 84960446833     PISSN: 15353702     EISSN: 15353699     Source Type: Journal    
DOI: 10.1177/1535370214565975     Document Type: Article

References (68)

1. Trapp BD, Peterson J, Ransohoff RM, Rudick R, Mork S, Bo L. Axonal transection in the lesions of multiple sclerosis. N Engl J Med 1998;338:278–85
2. Waxman SG. Demyelinating diseases—new pathological insights, new therapeutic targets. N Engl J Med 1998;338:323–5
3. Scolding N, Franklin R. Axon loss in multiple sclerosis. Lancet 1998;352:340–1
4. Wingerchuk DM, Weinshenker BG. Multiple sclerosis: epidemiology, genetics, classification, natural history, and clinical outcome measures. Neuroimaging Clin N Am 2000;10:611–24, vii
5. Kister I, Chamot E, Salter A, Cutter G, Bacon T, Kalina J, Herbert J. Natural history of MS symptoms: perceived disease impact across disease span in nine neurologic domains among enrollees in North American Research Committee on Multiple Sclerosis (NARCOMS) Registry. Neurology 2012;78:19–27
6. Vukusic S, Confavreux C. Natural history of multiple sclerosis. Presse Med 2010;39:359–62
7. Kantarci OH, Weinshenker BG. Natural history of multiple sclerosis. Neurol Clin 2005;23:17–38
8. Tremlett H, Zhao Y, Devonshire V. Natural history of secondaryprogressive multiple sclerosis. Multiple Sclerosis 2008;14:314–24
9. Koch M, Kingwell E, Rieckmann P, Tremlett H. The natural history of primary progressive multiple sclerosis. Neurology 2009;73:1996–2002
10. Crawford DK, Mangiardi M, Xia X, López-Valdés HE, Tiwari Woodruff SK. Functional recovery of callosal axons following demyelination: a critical window. Neuroscience 2009;164:1407–21
11. Lassmann H, Bruck W, Lucchinetti CF. The immunopathology of multiple sclerosis: an overview. Brain Pathol 2007;17:210–8
12. Chang A, Tourtellotte WW, Rudick R, Trapp BD. Premyelinating oligodendrocytes in chronic lesions of multiple sclerosis. N Engl J Med 2002;346:165–73
13. Frischer JM, Bramow S, Dal-Bianco A, Lucchinetti CF, Rauschka H, Schmidbauer M, Laursen H, Sorensen PS, Lassmann H. The relation between inflammation and neurodegeneration in multiple sclerosis brains. Brain 2009;132:1175–89
14. Mitew S, Hay CM, Peckham H, Xiao J, Koenning M, Emery B. Mechanisms regulating the development of oligodendrocytes and central nervous system myelin. Neuroscience 2014;276:29–47
15. Jiang Y, Yang Y, Zhang B, Peng F, Bao J, Hu X. Cerebrospinal fluid levels of iodothyronines and nerve growth factor in patients with multiple sclerosis and neuromyelitis optica. Neuro Endocrinol Lett 2009;30:85–90
16. Durand B, Raff M. A cell-intrinsic timer that operates during oligodendrocyte development. Bioessays 2000;22:64–71
17. Tokumoto YM, Tang DG, Raff MC. Two molecularly distinct intracellular pathways to oligodendrocyte differentiation: role of a p53 family protein. EMBO J 2001;20:5261–8
18. Billon N, Terrinoni A, Jolicoeur C, McCarthy A, Richardson WD, Melino G, Raff M. Roles for p53 and p73 during oligodendrocyte development. Development 2004;131:1211–20
19. Rogister B, Ben-Hur T, Dubois-Dalcq M. From neural stem cells to myelinating oligodendrocytes. Mol Cell Neurosci 1999;14:287–300
20. Mukhi S, Brown DD. Transdifferentiation of tadpole pancreatic acinar cells to duct cells mediated by Notch and stromelysin-3. Dev Biol 2011;351:311–7
21. Franco PG, Silvestroff L, Soto EF, Pasquini JM. Thyroid hormones promote differentiation of oligodendrocyte progenitor cells and improve remyelination after cuprizone-induced demyelination. Exp Neurol 2008;212:458–67
22. Fernandez M, Giuliani A, Pirondi S, D’Intino G, Giardino L, Aloe L, Levi-Montalcini R, Calza L. Thyroid hormone administration enhances remyelination in chronic demyelinating inflammatory disease. Proc Natl Acad Sci USA 2004;101:16363–8
23. Harsan LA, Steibel J, Zaremba A, Agin A, Sapin R, Poulet P, Guignard B, Parizel N, Grucker D, Boehm N, Miller RH, Ghandour MS. Recovery from chronic demyelination by thyroid hormone therapy: myelinogenesis induction and assessment by diffusion tensor magnetic resonance imaging. J Neurosci 2008;28:14189–201
24. Silvestroff L, Bartucci S, Pasquini J, Franco P. Cuprizone-induced demyelination in the rat cerebral cortex and thyroid hormone effects on cortical remyelination. Exp Neurol 2012;235:357–67
25. Taylor LC, Gilmore W, Ting JP-Y, Matsushima GK. Cuprizone induces similar demyelination in male and female C57BL/6 mice and results in disruption of the estrous cycle. J Neurosci Res 2010;88:391–402
26. Jeon H, Ai J, Sabri M, Tariq A, Shang X, Chen G, Macdonald RL. Neurological and neurobehavioral assessment of experimental subarachnoid hemorrhage. BMC Neurosci 2009;10:103
27. Franco-Pons N, Torrente M, Colomina MT, Vilella E. Behavioral deficits in the cuprizone-induced murine model of demyelination/remyelination. Toxicol Lett 2007;169:205–13
28. Kuhlmann T, Miron V, Cui Q, Wegner C, Antel J, Bruck W. Differentiation block of oligodendroglial progenitor cells as a cause for remyelination failure in chronic multiple sclerosis. Brain 2008;131:1749–58
29. Traka M, Arasi K, Avila RL, Podojil JR, Christakos A,Miller SD, Soliven, Popko B. A genetic mouse model of adult-onset, pervasive central nervous system demyelination with robust remyelination. Brain 2010;133:3017–29
30. Romero A, Dios S, Bremont M, Figueras A, Novoa B. Interaction of the attenuated recombinant rIHNV-Gvhsv GFP virus with macrophages from rainbow trout (Oncorhynchus mykiss). Vet Immunol Immunopathol 2011;140:119–29
31. Weinshenker BG. The natural history of multiple sclerosis: update 1998. Semin Neurol 1998;18:301–7
32. Weinshenker BG, Bass B, Rice GP, Noseworthy J, Carriere W, Baskerville J, Ebers GC. The natural history of multiple sclerosis: a geographically based study. I. Clinical course and disability. Brain 1989;112:133–46
33. Degenhardt A, Ramagopalan SV, Scalfari A, Ebers GC. Clinical prognostic factors in multiple sclerosis: a natural history review. Nat Rev Neurol 2009;5:672–82
34. Tremlett H, Zhao Y, Devonshire V. Natural history comparisons of primary and secondary progressive multiple sclerosis reveals differences and similarities. J Neurol 2009;256:374–81
35. Prineas JW, Connell F. Remyelination in multiple sclerosis. Ann Neurol 1979;5:22–31
36. Reynolds R, Cenci di Bello I, Dawson M, Levine J. The response of adult oligodendrocyte progenitors to demyelination in EAE. Prog Brain Res 2001;132:165–74
37. Back SA, Tuohy TM, Chen H, Wallingford N, Craig A, Struve J, Luo NL, Banine F, Liu Y. Hyaluronan accumulates in demyelinated lesions and inhibits oligodendrocyte progenitor maturation. Nat Med 2005;11:966–72
38. Franklin RJ, Ffrench-Constant C. Remyelination in the CNS: from biology to therapy. Nat Rev Neurosci 2008;9:839–55
39. Pagani E, Rocca MA, Gallo A, Rovaris M, Martinelli V, Comi G, Filippi M. Regional brain atrophy evolves differently in patients with multiple sclerosis according to clinical phenotype. Am J Neuroradiol 2005;26:341–6
40. Trapp BD, Nave KA. Multiple sclerosis: an immune or neurodegenerative disorder? Annu Rev Neurosci 2008;31:247–69
41. Weinstock-Guttman B, Bhasi K, Badgett D, Tamano-Blanco M, Minhas M, Feichter J, Patrick K, Munschauer F, Bakshi R, Ramanathan M. Genomic effects of once-weekly, intramuscular interferon- beta1a treatment after the first dose and on chronic dosing: relationships to 5-year clinical outcomes in multiple sclerosis patients. J Neuroimmunol 2008;205:113–25
42. Karussis D, Teitelbaum D, Sicsic C, Brenner T. Long-term treatment of multiple sclerosis with glatiramer acetate: natural history of the subtypes of anti-glatiramer acetate antibodies and their correlation with clinical efficacy. J Neuroimmunol 2010;220:125–30
43. Buttinelli C, Clemenzi A, Borriello G, Denaro F, Pozzilli C, Fieschi C. Mitoxantrone treatment in multiple sclerosis: a 5-year clinical and MRI follow-up. Eur J Neurol 2007;14:1281–7
44. Trojano M, Russo P, Fuiani A, Paolicelli D, Di Monte E, Granieri E, Rosati G, Savettieri G, Comi G, Livrea P. The Italian Multiple Sclerosis Database Network (MSDN): the risk of worsening according to IFNbeta exposure in multiple sclerosis. Mult Scler 2006;12:578–85
45. Van der Walt A, Butzkueven H, Kolbe S, Marriott M, Alexandrou E, Gresle M, Egan G, Kilpatrick T. Neuroprotection in multiple sclerosis: a therapeutic challenge for the next decade. Pharmacol Ther 2010;126:82–93
46. Zulewski H. [Hypothyroidism]. Ther Umsch 2011;68:315–20
47. Rodriguez-Pena A, Ibarrola N, Iniguez MA, Munoz A, Bernal J. Neonatal hypothyroidism affects the timely expression of myelinassociated glycoprotein in the rat brain. J Clin Invest 1993;91:812–8
48. Dussault JH, Ruel J. Thyroid hormones and brain development. Annu Rev Physiol 1987;49:321–34
49. Ibarrola N, Mayer-Proschel M, Rodriguez-Pena A, Noble M. Evidence for the existence of at least two timing mechanisms that contribute to oligodendrocyte generation in vitro. Dev Biol 1996;180:1–21
50. Ahlgren SC, Wallace H, Bishop J, Neophytou C, Raff MC. Effects of thyroid hormone on embryonic oligodendrocyte precursor cell development in vivo and in vitro. Mol Cell Neurosci 1997;9:420–32
51. Billon N, Jolicoeur C, Tokumoto Y, Vennstrom B, Raff M. Normal timing of oligodendrocyte development depends on thyroid hormone receptor alpha 1 (TR alpha 1). EMBO J 2002;21:6452–60
52. Carre JL, Demerens C, Rodriguez-Pena A, Floch HH, Vincendon G, Sarlieve LL. Thyroid hormone receptor isoforms are sequentially expressed in oligodendrocyte lineage cells during rat cerebral development. J Neurosci Res 1998;54:584–94
53. Gao FB, Apperly J, Raff M. Cell-intrinsic timers and thyroid hormone regulate the probability of cell-cycle withdrawal and differentiation of oligodendrocyte precursor cells. Dev Biol 1998;197:54–66
54. Baxi EG, Schott JT, Fairchild AN, Kirby LA, Karani R, Uapinyoying P, Pardo-Villamizar C, Rothstein JR, Bergles DE, Calabresi PA. A selective thyroid hormone beta receptor agonist enhances human and rodent oligodendrocyte differentiation. Glia 2014;62:1513–29
55. Fu AL, Zhou CY, Chen X. Thyroid hormone prevents cognitive deficit in a mouse model of Alzheimer’s disease. Neuropharmacology 2010;58:722–9
56. Sawano E, Negishi T, Aoki T, Murakami M, Tashiro T. Alterations in local thyroid hormone signaling in the hippocampus of the SAMP8 mouse at younger ages: association with delayed myelination and behavioral abnormalities. J Neurosci Res 2013;91:382–92
57. Noseworthy JH, Lucchinetti C, Rodriguez M, Weinshenker BG. Multiple sclerosis. N Engl J Med 2000;343:938–52
58. Fancy SP, Kotter MR, Harrington EP, Huang JK, Zhao C, Rowitch DH, Franklin RJ. Overcoming remyelination failure in multiple sclerosis and other myelin disorders. Exp Neurol 2010;225:18–23
59. Calza L, Fernandez M, Giuliani A, Aloe L, Giardino L. Thyroid hormone activates oligodendrocyte precursors and increases a myelinforming protein and NGF content in the spinal cord during experimental allergic encephalomyelitis. Proc Natl Acad Sci USA 2002;99:3258–63
60. Calza L, Fernandez M, Giuliani A, D’Intino G, Pirondi S, Sivilia S, Paradisi M, Desordi N, Giardino L. Thyroid hormone and remyelination in adult central nervous system: a lesson from an inflammatorydemyelinating disease. Brain Res Brain Res Rev 2005;48:339–46
61. Kondo T. [Cell-intrinsic timer regulating oligodendrocyte development]. Tanpakushitsu Kakusan Koso 2001;46:821–8
62. Walker P, Weichsel ME Jr, Fisher DA, Guo SM. Thyroxine increases nerve growth factor concentration in adult mouse brain. Science 1979;204:427–9
63. Althaus HH. Remyelination in multiple sclerosis: a new role for neurotrophins? Prog Brain Res 2004;146:415–32
64. Dell’acqua M, Lorenzini L, D’Intino G, Sivilia S, Pasqualetti P, Panetta V, Paradisi M, Filippi M, Baiguera C, Pizzi M, Giardino L, Rossini PM, Calzà L. Functional and molecular evidence of myelin- and neuroprotection by thyroid hormone administration in experimental allergic encephalomyelitis. Neuropathol Appl Neurobiol 2012;38:454–70
65. Linington C, Engelhardt B, Kapocs G, Lassman H. Induction of persistently demyelinated lesions in the rat following the repeated adoptive transfer of encephalitogenic T cells and demyelinating antibody. J Neuroimmunol 1992;40:219–24
66. Kornek B, Storch MK, Weissert R, Wallstroem E, Stefferl A, Olsson T, Linington C, Schmidbauer M, Lassmann H. Multiple sclerosis and chronic autoimmune encephalomyelitis: a comparative quantitative study of axonal injury in active, inactive, and remyelinated lesions. Am J Pathol 2000;157:267–76
67. Patrikios P, Stadelmann C, Kutzelnigg A, Rauschka H, Schmidbauer M, Laursen H, Sorensen PS, Bruck W, Lucchinetti C, Lassmann H. Remyelination is extensive in a subset of multiple sclerosis patients. Brain 2006;129:3165–72
68. Vose LR, Vinukonda G, Jo S, Miry O, Diamond D, Korumilli R, Arshad A, Zia MT, Hu F, Kayton RJ, Gamma EF, Ballabh P. Treatment with thyroxine restores myelination and clinical recovery after intraventricular hemorrhage. J Neurosci 2013;33:17232–46